Filter results
You can narrow down the results using the filters
Audience
Topics
Our work
Year
22 results
-
General Practice in Aged Care Incentive – Vodcasts
Find vodcast video's for the General Practice in Aged Care Incentive. -
Fact sheets and patient journeys
Find fact sheets and patient journeys for the General Practice in Aged Care Incentive. -
Aged care residents, their families and carers
Find frequently asked questions and information kits for General Practice in Aged Care Incentive aged care residents, their families and carers. -
Aged care experts and peak bodies
Find information kits for General Practice in Aged Care Incentive aged care experts and peak bodies. -
Primary care peak bodies
Find information kits for General Practice in Aged Care Incentive primary care peak bodies. -
GPs and practices
Find program guidelines, frequently asked questions, and information kits for General Practice in Aged Care Incentive GPs and practices. -
Residential aged care providers
Find frequently asked questions and information kits for General Practice in Aged Care Incentive residential aged care providers. -
Resources for First Nations people
Find MyMedicare fact sheets, information animations and a poster for First Nations health workers and patients. -
Resources for MyMedicare patients
Find fact sheets and frequently asked questions for MyMedicare patients. -
Resources for MyMedicare general practices and healthcare providers
Find fact sheets, frequently asked questions, brochures and the patient registration form for MyMedicare general practices and healthcare providers. -
Life Saving Drugs Program resources – Gaucher disease
A collection of resources for health professionals to help people with Gaucher disease (type 1) access the following drugs under the Life Saving Drugs Program: imiglucerase (Cerezyme®), velaglucerase (VPRIV®), taliglucerase (Elelyso®) and eliglustat (Cerdelga®). -
Life Saving Drugs Program resources – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D)
A collection of resources for health professionals to help people with infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) access sebelipase alfa (Kanuma®) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria
The PNH review considered the medicine eculizumab. The Expert Panel considered this review at its October 2020 meeting. These resources provide a summary of the review and recommendations. -
Life Saving Drugs Program resources – Perinatal- and infantile-onset hypophosphatasia (HPP)
A collection of resources for health professionals to help people with perinatal- or infantile-onset hypophosphatasia (HPP) access asfotase alfa (Strensiq®) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)
A collection of resources for health professionals to help people with mucopolysaccharidosis type I (MPS I) access laronidase (Aldurazyme®) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)
A collection of resources for health professionals to help people with mucopolysaccharidosis type II (MPS II) access idursulfase (Elaprase®) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)
A collection of resources for health professionals to help people with mucopolysaccharidosis type IVA (MPS IVA) access elosulfase alfa (Vimizim®) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)
A collection of resources for health professionals to help people with mucopolysaccharidosis type VI (MPS VI) access galsulfase (Naglazyme®) under the Life Saving Drugs Program (LSDP). -
Life Saving Drugs Program resources – Pompe disease
A collection of resources for health professionals to help people with Pompe disease access alglucosidase alfa (Myozyme®) and avalglucosidase alfa (Nexviazyme®) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Hereditary tyrosinaemia type 1
A collection of resources for health professionals to help people with hereditary tyrosinaemia type 1 access nitisinone (Orfadin® and Nityr™) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Late-Infantile onset batten disease (CLN2 disease)
A collection of resources for health professionals to help people with CLN2 disease access cerliponase alfa (Brineura®) under the Life Saving Drugs Program. -
Life Saving Drugs Program resources – Fabry disease
A collection of resources for health professionals to help people with Fabry disease access the following drugs under the Life Saving Drugs Program: agalsidase alfa (Replagal®), agalsidase beta (Fabrazyme®).